This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PYY / Peptide YY · IHC design guide
Design Immunohistochemistry for PYY
Plan paraffin-section PYY IHC using gastrointestinal endocrine cells as a positive staining reference (HPA tissue IHC). The catalog antibody has documented chromogenic staining in human appendicitis and small intestine sections (datasheet A04223-1); account for PYY secretion when interpreting signal (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
PYY Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Secreted (UniProt); tissue compartment unreported (HPA tissue IHC) | |
| Staining pattern | Selective GI enteroendocrine-cell staining (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A04223-1) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Secreted PYY: RNA and protein sites may differ (HPA tissue IHC) | |
| Regulation | Regulation unreported (UniProt) | |
| Isoform / epitope | 2 isoforms; check epitopes against processing sites (UniProt) |
Section 1
Recommended PYY IHC & IF Protocols
The catalog antibody protocol is accompanied by two published chromogenic PYY IHC protocols for paraffin sections (PMC3306780; PMC12834159).
| Sample | Paraffin-embedded human appendicitis tissue tissues; fixative not specified (datasheet A04223-1) |
| Fixation | Image fixative and duration unreported (datasheet A04223-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A04223-1) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A04223-1) |
| Primary antibody | Rabbit anti-PYY, 1μg/ml (datasheet A04223-1) |
| Primary incubation | Overnight at 4 °C (datasheet A04223-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A04223-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | PYY-positive staining in endocrine cells of appendix (HPA tissue IHC: High). HPA tissue profile: Selective expression of enteroendocrine cells in the gastrointestinal tract. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate retrieval at pH 6 for the catalog antibody (datasheet: A04223-1); neither published excerpt specifies retrieval (PMC3306780; PMC12834159).
Section 2
What Is the Expected PYY Staining Pattern?
PYY is a secreted peptide with no transmembrane segment (UniProt P10082: subcellular location and topology). In paraffin section IHC, expect selective staining of gastrointestinal enteroendocrine cells, with high staining reported in appendix, colon, duodenum, rectum and small intestine (HPA: tissue IHC). HPA rates the tissue pattern Enhanced but notes only medium consistency with RNA expression because a secreted protein’s RNA and protein locations can differ (HPA: reliability description).
| Distinct positive cells are scattered among gastrointestinal epithelial cells, while neighboring cells remain largely unstained. | This fits selective enteroendocrine expression (HPA: tissue IHC). Assess the pattern by cell identity as well as intensity: HPA reports High staining in endocrine cells at five gastrointestinal sites, rather than uniform staining across the tissue (HPA: tissue IHC). |
| The strongest signal appears nuclear, membranous or uniformly across many cell types. | Recheck compartment and morphology. PYY is secreted and has no transmembrane segment (UniProt P10082: subcellular location and topology); HPA provides no image based ICC-IF subcellular assignment (HPA: subcellular). A dominant nuclear or membrane pattern is therefore unsupported, while even cytoplasmic staining needs the expected cell distribution. |
| Strong chromogen appears in adipocytes, respiratory epithelium or other cells outside the expected endocrine population. | Treat it as a possible false positive and investigate antibody cross-reactivity or endogenous detection activity. HPA reports PYY as Not detected in adipose adipocytes and bronchial respiratory epithelial cells (HPA: tissue IHC). A single unexpected positive site should not redefine the target’s distribution. |
| Weak color covers most tissue, including spaces between cells and the negative control. | This is more consistent with background than selective enteroendocrine staining (HPA: tissue IHC). In chromogenic IHC, nonspecific antibody binding, inadequate blocking or residual endogenous detection activity can produce widespread color (standard IHC practice); compare the slide with matched controls before scoring cells as positive. |
| No convincing endocrine cell signal appears in an appendix, colon, duodenum, rectum or small intestine section. | First confirm that the section contains identifiable endocrine cells and that the run’s controls worked. These are HPA High sites specifically in endocrine cells (HPA: tissue IHC), but their absence on one slide does not establish absent PYY expression; review antibody, retrieval and detection conditions as general IHC troubleshooting. |
💡Expected PYY appearanceCall a section positive when discrete gastrointestinal endocrine cells show clear cellular chromogen above neighboring cells (HPA: High in endocrine cells); diffuse tissue color or dominant nuclear or membrane staining is not the supported PYY pattern (HPA: tissue IHC; UniProt P10082: secreted, no transmembrane segment).
| Tissue and cell identity | Use the endocrine cell population in appendix, colon, duodenum, rectum or small intestine as the primary pattern reference (HPA: High in endocrine cells). HPA’s Not detected entries describe the specified cells in those tissues, not every cell in an entire organ (HPA: tissue IHC). |
| Secretion and compartment | PYY is secreted and lacks a transmembrane segment (UniProt P10082: subcellular location and topology). Cellular staining may reflect peptide before secretion; extracellular signal alone needs cautious interpretation. HPA lists no ICC-IF images or assigned intracellular location to establish a finer compartment pattern (HPA: subcellular). |
| Peptide processing and antibody epitope | The PYY record annotates a signal peptide at residues 1–28 and a propeptide at 68–97 (UniProt P10082: processing). An antibody’s recognized sequence could affect which PYY form is detected; the supplied records give no epitope, so do not infer mature peptide specificity. |
| Isoforms and antibody validation | UniProt lists 2 isoforms without their antibody epitopes (UniProt P10082: isoforms). HPA rates HPA010973 Enhanced and CAB016734 Supported for IHC (HPA: antibodies). Those ratings support their documented IHC validation status; they do not establish identical recognition of both isoforms. |
| RNA comparison and preparation limits | HPA reports intestine enriched RNA and warns that secreted protein can occupy a different tissue location from its RNA (HPA: RNA specificity and reliability description). Neither HPA nor UniProt supplies a target specific fixation effect here; evaluate retrieval and fixation changes as general IHC workflow variables only. |
| Situation | Likely cause | Next action |
|---|---|---|
| Known positive gastrointestinal tissue has no endocrine cell staining. | The expected population may be missing from the section, or the IHC run may have failed; HPA reports High staining specifically in endocrine cells (HPA: tissue IHC). | Check tissue morphology and a working positive control, then review antibody dilution, retrieval and detection steps as general IHC practice. Do not call PYY absent from a single failed section. |
| Every cell shows similarly strong chromogen. | A broad pattern conflicts with HPA’s selective enteroendocrine profile (HPA: tissue IHC); nonspecific binding or endogenous detection activity is possible (standard IHC practice). | Compare a no primary control, assess blocking and endogenous activity controls, and adjust detection conditions before scoring. Retain only cell associated signal clearly above surrounding tissue. |
| Unexpected adipocyte or respiratory epithelial staining appears. | Those specified cell types were Not detected in HPA tissue IHC (HPA: adipose tissue and bronchus); cross-reactivity or detection background may explain the discrepancy. | Verify the cell type and compare negative controls with a gastrointestinal positive section. Investigate reproducibility with an independently validated antibody before treating the unexpected site as PYY positive. |
| Signal is predominantly nuclear or membrane outlined. | PYY is annotated as secreted with no transmembrane segment (UniProt P10082: location and topology). HPA does not provide an ICC-IF image based finer location (HPA: subcellular). | Review morphology, counterstain and controls for localization error or background. Avoid assigning that compartment to PYY from this slide alone; compare with the selective endocrine cell pattern (HPA: tissue IHC). |
| Staining differs between antibodies or after a preparation change. | The record lists 2 isoforms and peptide processing, but supplies no antibody epitope or target specific fixation sensitivity (UniProt P10082: isoforms and processing). | Document antibody identity and preparation, then compare matched sections and controls. Interpret a change as assay dependent until the recognized PYY form and tissue pattern are independently supported. |
| Can IF/ICC use the same localization call? | HPA describes PYY as secreted but provides no ICC-IF images, main intracellular location or ICC validation entry for the listed antibodies (HPA: subcellular and antibodies). | Use the separate IF/ICC guide for assay design. Here, use HPA tissue IHC only to set an expected gastrointestinal endocrine cell distribution, without treating it as an IF/ICC compartment validation (HPA: tissue IHC; subcellular). |
Experiment evidence
IHC & IF images showing PYY staining
A04223-1 · IHCIHC analysis of Peptide YY/PYY using anti-Peptide YY/PYY antibody (A04223-1). Peptide YY/PYY was detected in paraffin-embedded section of hu
A04223-1 · IHCIHC analysis of Peptide YY/PYY using anti-Peptide YY/PYY antibody (A04223-1). Peptide YY/PYY was detected in a paraffin-embedded section of
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000131096-PYY/tissue/cerebral+cortex#imid_6091192
HPA · Small intestineHuman Protein Atlas IHC, Small intestine. Source: https://www.proteinatlas.org/ENSG00000131096-PYY/tissue/small+intestine#imid_4310117
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000131096-PYY/tissue/colon#imid_6091102
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000131096-PYY/tissue/liver#imid_6091111
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for PYY IHC & IF
🧪Run appendix first: its endocrine cells should stain for PYY (HPA: High in appendix endocrine cells). Use adipose tissue as the negative tissue, where adipocytes are not detected, and expect adjacent non-endocrine cells on the appendix slide to show only background (HPA: Not detected in adipose adipocytes; HPA: High in appendix endocrine cells).
Positive control tissue: Appendix (Endocrine cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for PYY; derive a cell-line control from the positive tissue's cell type (Endocrine cells) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary (secondary-only) slide, a concentration-matched rabbit isotype control, and a biological specificity control using PYY knockout tissue or peptide competition if available (caption: rabbit primary antibody; standard IHC practice). In appendix sections, check for endogenous peroxidase and biotin background because the reported detection uses a biotinylated secondary, streptavidin–biotin complex, and DAB (caption: SABC/DAB detection; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A04223-1 paraffin-section caption does not state the fixative (caption: fixative not stated). That caption reports citrate retrieval at pH 6 for 20 minutes, but does not establish that retrieval is required for every specimen (caption: heat-mediated citrate retrieval). Comparative ease of frozen-section IHC or IF is unreported; HPA lists no ICC-IF image-bearing cell lines for PYY, and appendix background from endogenous peroxidase or biotin should be checked with the stated detection method (HPA: no ICC-IF cell lines; caption: SABC/DAB detection; standard IHC practice).
HPA tissue IHC evidence for PYY
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Secreted protein, tissue location of RNA and protein is expected to differ.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Endocrine cells | High | Protein (IHC) | HPA → |
| Colon | Endocrine cells | High | Protein (IHC) | HPA → |
| Duodenum | Endocrine cells | High | Protein (IHC) | HPA → |
| Rectum | Endocrine cells | High | Protein (IHC) | HPA → |
| Small intestine | Endocrine cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced PYY IHC Tips
Use matched gastrointestinal controls and cell-level scoring to troubleshoot PYY staining in paraffin sections (HPA: selective enteroendocrine-cell expression).
How should I adjust antigen retrieval when PYY staining is weak?
Start with heat-mediated citrate retrieval at pH 6 for 20 minutes on paraffin sections (datasheet A04223-1). Keep an appendix endocrine-cell section in each run as a positive control (HPA: High in appendix endocrine cells), and compare retrieval changes against that section rather than judging a single specimen. If staining remains weak, adjust heating or cooling conditions one variable at a time while keeping citrate at pH 6; inspect morphology because excessive heating can damage sections (standard IHC practice). The caption used 1 µg/ml primary antibody overnight at 4°C, so check primary incubation and detection before attributing all loss to retrieval (datasheet A04223-1).
Could fixation explain inconsistent PYY staining across paraffin sections?
Target-specific fixation sensitivity is unknown: the paraffin-section caption does not state a fixative (datasheet A04223-1). Record the fixative, fixation duration, tissue thickness and processing history for each specimen, then compare sections prepared alike using the same citrate pH 6 retrieval for 20 minutes (datasheet A04223-1; standard IHC practice). If a weak case has poor morphology or patchy staining, examine matched control tissue before changing antibody concentration; fixation and processing differences can affect antigen access in IHC (standard IHC practice). Do not infer a PYY-specific fixation effect from its secreted annotation, modifications or tissue staining pattern (UniProt P10082; HPA: tissue IHC).
Where should convincing PYY staining appear in a gastrointestinal section?
Look first for staining in gastrointestinal endocrine cells, including those in appendix, colon, duodenum, rectum and small intestine (HPA: High in endocrine cells at these sites). PYY is annotated as secreted and has no transmembrane segment, so a crisp plasma-membrane outline alone is not the expected pattern to use as proof of specificity (UniProt P10082: subcellular location and topology). Compare cell-level signal with morphology and a matched negative-control section; diffuse extracellular colour needs cautious interpretation for a secreted peptide (UniProt P10082; standard IHC practice). HPA rates tissue staining as Enhanced but notes medium RNA–protein consistency and that secretion can separate protein location from RNA location (HPA: reliability description).
Can this stain distinguish PYY isoforms or processed peptide forms?
Do not score this antibody as isoform-specific without epitope mapping or direct validation: PYY has 2 annotated isoforms, while the supplied caption does not identify the antibody epitope (UniProt P10082: isoforms; datasheet A04223-1). The precursor is 97 amino acids long, with a signal segment at residues 1–28 and an annotated propeptide at 68–97 (UniProt P10082: processing). Phosphoserine at 41 and tyrosine amide at 64 are annotated modifications; their effects on antibody binding are unknown here (UniProt P10082: modified residues). If processed forms matter, obtain epitope information and validate specificity against the forms of interest before interpreting differences in chromogenic intensity (standard IHC practice).
How should I adapt PYY detection for multiplex immunofluorescence?
Treat IF as a separate validation exercise because the supplied product evidence describes chromogenic staining of paraffin sections, with no IF result (datasheet A04223-1). Multiplex PYY with a validated endocrine-cell marker and check whether signal falls in the expected gastrointestinal cell population (HPA: selective enteroendocrine-cell expression; standard IF practice). Choose spectrally separated fluorophores, favour a far-red channel if the tissue has substantial shorter-wavelength autofluorescence, and inspect single-stain and unstained controls (standard IF practice). For an intracellular epitope, test gentle permeabilisation; for an accessible extracellular epitope, compare without permeabilisation, since the antibody epitope is unspecified and PYY is secreted without a transmembrane segment (datasheet A04223-1; UniProt P10082).
How can I separate PYY staining from chromogenic background?
The documented paraffin-section method uses 10% goat-serum block, a biotinylated secondary, streptavidin–biotin detection and DAB (datasheet A04223-1). Run a no-primary control through the same detection steps, and include a peroxidase block as a general chromogenic IHC measure before interpreting brown deposits as PYY (standard IHC practice). If background follows the biotin-based detection system, assess endogenous biotin and consider an appropriately validated alternative detection system (standard IHC practice). Compare the result with endocrine cells in appendix as a positive reference and adipocytes in adipose tissue as a negative reference; these HPA patterns guide control selection but do not validate every specimen (HPA: High in appendix endocrine cells; Not detected in adipose adipocytes).
What should I count when comparing PYY staining between sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the gastrointestinal region and endocrine-cell denominator before scoring, because HPA reports selective PYY expression in enteroendocrine cells rather than uniform tissue staining (HPA: tissue profile). Report the percentage of positive endocrine cells, or an H-score combining their percentage and intensity, using the same threshold and DAB development settings across sections (standard IHC quantification practice). If cell identification is uncertain, report positive-cell density per mm² of evaluable mucosa and document how endocrine cells were identified (standard IHC quantification practice). Normalise to endocrine-cell count or evaluable tissue area, as appropriate, and exclude folds, necrosis and tissue edges by a rule set before scoring (standard IHC practice).
Which apparent PYY-positive patterns should make me question specificity?
A convincing result should localise to gastrointestinal endocrine cells and be reproducible in a matched positive-control section (HPA: selective enteroendocrine-cell expression; standard IHC practice). Treat predominant staining of unrelated cell types, a sharp membrane-only outline, or widespread nuclear colour cautiously: PYY is secreted and lacks a transmembrane segment (UniProt P10082: location and topology). Compare suspect deposits with the no-primary control, especially at section edges, necrotic regions and sites with endogenous peroxidase activity (standard chromogenic IHC practice). Negative staining in a particular section does not by itself prove absent PYY; assess morphology, retrieval and the run control, and remember that RNA and protein locations may differ for a secreted protein (HPA: reliability description; standard IHC practice).
Boster reagents
Best PYY / Peptide YY IHC Antibodies
The IHC-validated anti-PYY antibody has real chromogenic IHC data from human paraffin sections of appendicitis and small intestine tissue (A04223-1 IHC captions).
Real IHC data
Anti-Peptide YY/PYY Antibody
Cat # A04223-1
A04223-1 is listed for human IHC and shown on paraffin sections of human appendicitis tissue (catalog applications/reactivity; A04223-1 IHC caption). A second IHC image shows the same SKU on a paraffin section of human small intestine (A04223-1 IHC caption).
Which to pick: Choose A04223-1 for human paraffin-section IHC: it is a rabbit polyclonal antibody listed for human IHC, with chromogenic images from both tissues (catalog host/dilution_raw/applications/reactivity; A04223-1 IHC captions). The captions do not report the fixative, so fixation and tissue suitability are unconfirmed (A04223-1 IHC captions). The payload provides no validated IF/ICC or cross-species option (catalog applications/reactivity/if_image_alts). The selected A04223-1 tissue-IHC caption documents paraffin sections, but does not specify the fixative (selected-SKU IHC image A04223-1).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P10082 (PYY_HUMAN, Peptide YY).
- Human Protein Atlas. PYY tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. PYY subcellular location (ICC-IF): Secreted.
- Human Protein Atlas. PYY antibody validation summary (2 antibodies).
- Free fatty acid receptor 1 stimulates cAMP production and gut hormone secretion through Gq-mediated activation of adenylate cyclase 2. Molecular metabolism 2023 — PMC10394103.
- Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Digestive diseases and sciences 2012 — PMC3306780.
- Defining G protein-coupled receptor peptide ligand expressomes and signalomes in human and mouse islets. Cellular and molecular life sciences : CMLS 2018 — PMC6061145.
- Phascolarctobacterium faecium reduces food intake via PYY signaling, contributing to the mitigation of body weight gain in diet-induced obese mice. Gut microbes 2026 — PMC12834159.
- PubMed PMID:8318545 — UniProt-cited evidence.
- PubMed PMID:16625196 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for PYY (Peptide YY). Expected localisation Secreted (UniProt); tissue compartment unreported (HPA tissue IHC). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A04223-1). Validated IHC antibody: A04223-1 at 1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Endocrine cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human appendicitis tissue tissues; fixative not specified (datasheet A04223-1); 2. Fixation: Image fixative and duration unreported (datasheet A04223-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A04223-1); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A04223-1); 8. Primary antibody: Rabbit anti-PYY, 1μg/ml (datasheet A04223-1); 9. Primary incubation: Overnight at 4 °C (datasheet A04223-1). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Secreted PYY: RNA and protein sites may differ (HPA tissue IHC); Isoform / epitope: 2 isoforms; check epitopes against processing sites (UniProt); Regulation: Regulation unreported (UniProt). Evidence: UniProt P10082, HPA tissue IHC · Enhanced, HPA ICC-IF · Secreted, Datasheet A04223-1, PMC3306780, PMC12834159. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/PYY/immunohistochemistry-ihc-guide.